Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be ...

Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have ...

By using a compound derived from a Himalayan fungus and used for centuries in Chinese medicine as a jumping off point, ...

Michael Wolff was at the "edge of a cliff" when he was diagnosed with a cancer that affects less than 300 patients a year in the U.S.

St. Pete doctor credits “Patient No More Series” for insurer’s change in policy for popular breast cancer surgery.

Waksal, who is not a medical doctor, imported the veterinary drug along with other “unapproved ingredients” from Colombia.

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Researchers from Johns Hopkins University have identified three subtypes of senescent skin cells with distinct shapes, ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...